Pharmacokinetics of the estrogen receptor subtype-selective ligands, PPT and DPN: quantification using UPLC-ES/MS/MS

Estatira Sepehr1, Marketa Lebl-Rinnova, Meagan K Mann

  • 1National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA.

Related Concept Videos